Inotropic therapy in heart failure: General aspects and clinical results;Tratamiento inotrópico en la insuficiencia cardíaca: Aspectos generales y resultados clínicos

Medicina Clinica

Volumn 122, Issue 7, 2004, Pages 269-274

  Manito, Nicolás ^a   Kaplinsky, Edgardo J ^a   Pujol, Ramón ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Dobutamine; Heart failure; Inotropic agents; Levosimendan; Milrinone

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARVEDILOL; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENOXIMONE; FLOSEQUINAN; IBOPAMINE; INOTROPIC AGENT; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; PLACEBO; XAMOTEROL;

ACUTE HEART FAILURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EOSINOPHILIA; ERYTHEMA; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; INOTROPISM; LONG TERM CARE; META ANALYSIS; MULTICENTER STUDY; PALLIATIVE THERAPY; PHLEBITIS; PRURITUS; REVIEW;

EID: 1842814234     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058377     Document Type: Review

References (59)

1. Boix Martínez R, Almazán Isla J, Medrano Albero J. Mortalidad por insuficiencia cardíaca en España, 1977-1998. Rev Esp Cardiol 2002;55: 219-26.
2. Chin MH, Goldman L. Correlates of major complications of death in patients admitted to the hospital with congestive heart failure. Arch Int Med 1996;156:1814-20.
3. Hadelman GA, Croft JB, Giles WH, Rashidee A. Hospitalisations of patients with heart failure: national hospital discharge survey 1985-1005. Am Heart J 1999;137:352-60.
4. Stevenson LW. Inotropic therapy for Heart failure. N Engl J Med 1998; 339:1848-50.
5. Rapundalo ST, Solaro RJ, Kranias EG. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phophorilation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989;64:104-11.
6. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
7. Insel PA. Adrenergic receptors: evolving concepts and clinical implications. N Engl J Med 1996;334:580-5.
8. Steen PA, Tinker JH, Pluth JR, Barnhost DA, Tarhan S. Efficacy of dopamine, dobutamine and epinephrine during emergence from cardiopulmonary bypass in man. Circulation 1978;57:378-84.
9. Goldberg LI, Raifer SI. Dopamine receptors: application in clinical cardiology. Circulation 1985;72:245-8.
10. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. I. Comparative systemic and renal effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978;58:466-75.
11. Ruffolo RR Jr. Review: the pharmacology of dobutamine. Am J Med Sci 1987;294:244-8.
12. Colucci WS, Denniss AR, Leatherman GF, Quigg RJ, Ludmer PL, Marsh JD, et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure: dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 1988;81:1103-10.
13. DiBianco R. Acute positive inotropic intervention: the phosphodiesterase inhibition. Am Heart J 1991;121:1871-5.
14. Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986;73(3 PT 2):175-83.
15. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients severe heart failure: doseresponse relationships and comparison with nitroprusside. J Clin Invest 1985;75:642-9.
16. Lee JC, Dowing SE. Cyclic AMP and the pathogenesis of myocardial injury. Res Commun Chem Pathol Pharmacol 1980;27:305-18.
17. Martorana PA. The role of cyclic AMP in isoprenaline-induced cardiac necroses in the rat. J Pharm Pharmacol 1971;23:200-3.
18. Podzuweit T, Lubbe WF, Opie LH. Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs. Lancet 1976;1:341-2.
19. Ebbesen P. Myocardial degeneration in mice treated with dibutytyl cyclic AMP and/or theophylline. Virchows Arch 1976;372:89-95.
20. Sandusky GE, Means JR, Todd GC. Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol Pathol 1990;18:268-78.
21. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998;41:207-24.
22. Katz AM. Metabolism of the failing heart. Cardioscience 1993,4:199-203.
23. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic Herat failure. N Engl J Med 1991;325:1468-75.
24. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinona among patients with severe heart failure. N Engl J Med 1998;339:1810-6.
25. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
26. Van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of negative drug trials in patients with severe chronic heart failure. Int J Cardiol 2001;80:19-27.
27. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Retorne WJ, Heinrich-Nols J, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) Trial Heart 1996;76:223-31.
28. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximore Multicenter Trial Group. Circulation 1990;82:774-80.
29. Hampton JR, Van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomized study of effect of ibopamine on survival in patients with advanced Heart failure. Lancet 1997;349:971-7.
30. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-40.
31. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
32. Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977;56:468-72.
33. Leier CV, Huss P, Lewis RP, Unverferth DV. Drug-induced conditioning in congestive heart failure. Circulation 1982;65:1382-7.
34. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB Jr. Sustained improvement of cardiac function in patients after short term infusion of dobutamine. Circulation 1984;69:113-9.
35. Harjai KJ, Mehra MR, Ventura HO. Home inotropic therapy in advanced heart failure: cost analysis and outcomes. Chest 1997;112:1298-303.
36. Domínguez de Rozas JM, Guindo Soldevila J, Rodríguez Font E, Martinez Vílchez R. Los efectos hemodinámicos de la combinación de milrinona en la insuficiencia cardíaca refractaria al tratamiento con dopamina, dobutamina y/o nitroprusiato. Rev Esp Cardiol 1994;47:682-6.
37. Packer M, Leier CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 1987;75(Suppl 4):55-63.
38. Monrad ES, Baim DS, Smith HS, Lanouer A, Brauwald E, Grossman W. Effects of milrinone on coronary hemodinamics and myocardial energetics in patients with congestive heart failure. Circulation 1985;41:972-80.
39. Wu CC, Chen WJ, Cheng JJ, Hsieh YY, Lien WP. Local dermal hypersensitivity from dobutamine hydrochloride (Dobutrex solution) injection. Chest 1991;99:1547-8.
40. Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997;80:61-4.
41. Higginbotham MB, Russell SD, Mehra MR, Ventura HO. Bridging patients to cardiac transplantation. Congest Heart Fail 2000;6:238-42.
42. Galluci M, Christen A, Blanco GA. Asistencia circulatoria mecánica. En: Mautner B, editor. Cardiología basada en la evidencia y la experiencia de la Fundación Favaloro. Buenos Aires: Grupo Guía, 2003; p. 276-81.
43. Dies F, Krell MJ, Whitlow P, Liang CS, Goldenberg I, Applefeld MM, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [resumen]. Circulation 1986;74(Suppl 2):38.
44. Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomised double blind placebo-controlled study. Clin Pharmacol Ther 1998;63:682-5.
45. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomised Survival Trial (FIRST). Am Heart J 1999;138:78-86.
46. Capomolla S, Febo O, Opasich C, Guazzotti G, Caporotondi A, La Rovere MT, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001;3:601-10.
47. Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multi-center trial. Am Heart J 1999;138:247-53.
48. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 2002;287:1541-7.
49. Yusuf S, Teo KK. Inotropic agents increase mortality in patients with congestive heart failure [resumen]. Circulation 1990;82(Suppl 3):673.
50. Bristow MR, Shakar SF, Linseman JV, Lowes BD, Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001;7(Suppl 1):8-12.
51. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141-9.
52. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995;26(Suppl 1):10-9.
53. Holubarsch C. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1997;88(Suppl 2):12-20.
54. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxataion. J Cardiovasc Pharmacol 1995;25:794-801.
55. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-7.
56. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
57. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardual infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
58. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendán compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
59. Anguita Sánchez M. Nuevos fármacos para el tratamiento de la insuficiencia cardíaca. Med Clin (Barc) 2002;119:732-3.